For a long time, nicotine has been firmly labeled as a “carcinogen” by the public, and is closely linked to cigarettes, carrying a bad reputation for damaging health. New research from Harvard Medical School, however, has turned our conventional understanding of nicotine on its head. It was found that there was A significant positive correlation between nicotine receptor activation efficiency and Aβ protein clearance. This means that nicotine has the potential to become A key “weapon” in clearing harmful Aβ proteins from the brain, bringing new hope for the treatment of neurodegenerative diseases such as Alzheimer’s disease. At the same time, clinical data also provide strong support for the medical value of nicotine. In the treatment of Parkinson’s disease patients, the tremor improvement rate was as high as 62% in the treatment group using 4mg of nicotine patch daily. This remarkable data has forced people to re-examine the potential of nicotine in the medical field.
With the deepening of the research on the medical effects of nicotine, a battle has been quietly started around its indications. In terms of therapeutic research for Alzheimer’s disease, patient recruitment for Phase III clinical trials of nicotine transdermal patches is accelerating. If the trial is successful, it could open up entirely new treatment options for Alzheimer’s patients. In the field of mental illness, nicotine also shows a unique mechanism of action. Studies have shown that nicotine lozenges can regulate REM sleep in patients with depression, opening up a new path for depression treatment from the perspective of sleep regulation. Many scientific research teams and pharmaceutical companies have invested in the study of nicotine indications, trying to seize the opportunity in this emerging medical field.
At the technical level, the medical application of nicotine has also ushered in a major breakthrough. The innovation in targeted delivery technology is amazing, with exosome-loaded nicotine nanoparticles that penetrate the blood-brain barrier 20 times more efficiently than conventional methods. This breakthrough allows nicotine to reach the affected areas of the brain more precisely and efficiently to play a therapeutic role. At the same time, gene editing technology also provides a boost for the medical use of nicotine. Modification of nicotine acetylcholine receptors through CRISPR can greatly enhance the specificity of treatment, reduce side effects on other tissues and organs, and make the therapeutic effect of nicotine more significant and safe.
However, the development of the medical application of nicotine is not smooth sailing, and ethical issues have become a difficult problem in front of it. On the one hand, nicotine shows great potential for medical use; On the other hand, the risk of addiction cannot be ignored. The FDA’s new Risk Benefit assessment model (RBRM) aims to balance the two, but it has caused a lot of controversy in practical applications. Some argue that the model fails to adequately account for the complexity of nicotine addiction and may lead to an underestimation of potential risks for patients. According to a survey of physicians, 72% of neurologists support the development of non-addictive nicotine derivatives, reflecting the strong desire of medical professionals to address nicotine addiction and advance its medical use.
0 Comments